Cargando…
Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells
Glioblastoma is an invasive tumor of the central nervous system. Tumor recurrence resulting from ineffective current treatments, mainly due to the blood–brain barrier, highlights the need for innovative therapeutic alternatives. The recent availability of nanotechnology represents a novel targeted s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894954/ https://www.ncbi.nlm.nih.gov/pubmed/24531649 http://dx.doi.org/10.2147/IJN.S48136 |
_version_ | 1782299910568148992 |
---|---|
author | Tahmasebi Mirgani, Maryam Isacchi, Benedetta Sadeghizadeh, Majid Marra, Fabio Bilia, Anna Rita Mowla, Seyed Javad Najafi, Farhood Babaei, Esmael |
author_facet | Tahmasebi Mirgani, Maryam Isacchi, Benedetta Sadeghizadeh, Majid Marra, Fabio Bilia, Anna Rita Mowla, Seyed Javad Najafi, Farhood Babaei, Esmael |
author_sort | Tahmasebi Mirgani, Maryam |
collection | PubMed |
description | Glioblastoma is an invasive tumor of the central nervous system. Tumor recurrence resulting from ineffective current treatments, mainly due to the blood–brain barrier, highlights the need for innovative therapeutic alternatives. The recent availability of nanotechnology represents a novel targeted strategy in cancer therapy. Natural products have received considerable attention for cancer therapy because of general lower side effects. Curcumin is a new candidate for anticancer treatment, but its low bioavailability and water solubility represent the main disadvantages of its use. Here, curcumin was efficiently encapsulated in a nontoxic nanocarrier, termed dendrosome, to overcome these problems. Dendrosomal curcumin was prepared as 142 nm spherical structures with constant physical and chemical stability. The inhibitory role of dendrosomal curcumin on the proliferation of U87MG cells, a cellular model of glioblastoma, was evaluated by considering master genes of pluripotency and regulatory miRNA (microribonucleic acid). Methylthiazol tetrazolium assay and flow cytometry were used to detect the antiproliferative effects of dendrosomal curcumin. Annexin-V-FLUOS and caspase assay were used to quantify apoptosis. Real-time polymerase chain reaction was used to analyze the expression of OCT4 (octamer binding protein 4) gene variants (OCT4A, OCT4B, and OCT4B1), SOX-2 (SRY [sex determining region Y]-box 2), Nanog, and miR-145. Dendrosomal curcumin efficiently suppresses U87MG cells growth with no cytotoxicity related to dendrosome. Additionally, the accumulation of cells in the SubG(1) phase was observed in a time- and dose-dependent manner as well as higher rates of apoptosis after dendrosomal curcumin treatment. Conversely, nonneoplastic cells were not affected by this formulation. Dendrosomal curcumin significantly decreased the relative expression of OCT4A, OCT4B1, SOX-2, and Nanog along with noticeable overexpression of miR-145 as the upstream regulator. This suggests that dendrosomal curcumin reduces the proliferation of U87MG cells through the downregulation of OCT4 (octamer binding protein 4) variants and SOX-2 (SRY [sex determining region Y]-box 2) in an miR-145-dependent manner. |
format | Online Article Text |
id | pubmed-3894954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38949542014-01-27 Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells Tahmasebi Mirgani, Maryam Isacchi, Benedetta Sadeghizadeh, Majid Marra, Fabio Bilia, Anna Rita Mowla, Seyed Javad Najafi, Farhood Babaei, Esmael Int J Nanomedicine Original Research Glioblastoma is an invasive tumor of the central nervous system. Tumor recurrence resulting from ineffective current treatments, mainly due to the blood–brain barrier, highlights the need for innovative therapeutic alternatives. The recent availability of nanotechnology represents a novel targeted strategy in cancer therapy. Natural products have received considerable attention for cancer therapy because of general lower side effects. Curcumin is a new candidate for anticancer treatment, but its low bioavailability and water solubility represent the main disadvantages of its use. Here, curcumin was efficiently encapsulated in a nontoxic nanocarrier, termed dendrosome, to overcome these problems. Dendrosomal curcumin was prepared as 142 nm spherical structures with constant physical and chemical stability. The inhibitory role of dendrosomal curcumin on the proliferation of U87MG cells, a cellular model of glioblastoma, was evaluated by considering master genes of pluripotency and regulatory miRNA (microribonucleic acid). Methylthiazol tetrazolium assay and flow cytometry were used to detect the antiproliferative effects of dendrosomal curcumin. Annexin-V-FLUOS and caspase assay were used to quantify apoptosis. Real-time polymerase chain reaction was used to analyze the expression of OCT4 (octamer binding protein 4) gene variants (OCT4A, OCT4B, and OCT4B1), SOX-2 (SRY [sex determining region Y]-box 2), Nanog, and miR-145. Dendrosomal curcumin efficiently suppresses U87MG cells growth with no cytotoxicity related to dendrosome. Additionally, the accumulation of cells in the SubG(1) phase was observed in a time- and dose-dependent manner as well as higher rates of apoptosis after dendrosomal curcumin treatment. Conversely, nonneoplastic cells were not affected by this formulation. Dendrosomal curcumin significantly decreased the relative expression of OCT4A, OCT4B1, SOX-2, and Nanog along with noticeable overexpression of miR-145 as the upstream regulator. This suggests that dendrosomal curcumin reduces the proliferation of U87MG cells through the downregulation of OCT4 (octamer binding protein 4) variants and SOX-2 (SRY [sex determining region Y]-box 2) in an miR-145-dependent manner. Dove Medical Press 2014-01-13 /pmc/articles/PMC3894954/ /pubmed/24531649 http://dx.doi.org/10.2147/IJN.S48136 Text en © 2014 Mirgani et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Tahmasebi Mirgani, Maryam Isacchi, Benedetta Sadeghizadeh, Majid Marra, Fabio Bilia, Anna Rita Mowla, Seyed Javad Najafi, Farhood Babaei, Esmael Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells |
title | Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells |
title_full | Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells |
title_fullStr | Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells |
title_full_unstemmed | Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells |
title_short | Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells |
title_sort | dendrosomal curcumin nanoformulation downregulates pluripotency genes via mir-145 activation in u87mg glioblastoma cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894954/ https://www.ncbi.nlm.nih.gov/pubmed/24531649 http://dx.doi.org/10.2147/IJN.S48136 |
work_keys_str_mv | AT tahmasebimirganimaryam dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT isacchibenedetta dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT sadeghizadehmajid dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT marrafabio dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT biliaannarita dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT mowlaseyedjavad dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT najafifarhood dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells AT babaeiesmael dendrosomalcurcuminnanoformulationdownregulatespluripotencygenesviamir145activationinu87mgglioblastomacells |